Research Outcomes: Building Hope
Using Precision Medicine to Improve Pediatric Cancer Treatment
EXCITING UPDATE November 1, 2022: The largest academic collaboration of its kind was announced last month, and it builds off this St. Baldrick’s supported work. The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and St. Jude Children’s Research Hospital will collaborate to transform and accelerate the identification of vulnerabilities in pediatric cancers and translate them into better treatments.
Dr. Stegmaier said, “The Pediatric Cancer Dependency Map provided our community with a treasure trove of new data. However, the next critical step was to validate candidate gene targets emerging from this project. The St. Baldrick’s Foundation Robert J Arceci Innovation Award provided the critical funding for us to demonstrate the power of the Pediatric Cancer Dependency Map.
With St. Baldrick’s support, we validated new candidate therapeutic targets in childhood cancers, such as Ewing sarcoma and neuroblastoma, which have led to the launching of drug discovery efforts, and we have gained novel insights into the mechanistic underpinnings of these diseases. We were able to show our community the power of the project. I think we are just at the tip of the iceberg. We are all very excited about the promise of what is to come through this new large-scale collaboration.”
We are excited to see the impact this collaboration has in helping to conquer childhood cancer.
2022 Ambassador – Meet Natasha, St. Baldrick’s First International Ambassador
2022 Ambassador: Meet Rocco – A 5-Year-Old Full of Love, Kindness, and Faith
The Top 2021 Messages Worth Remembering
As we close a difficult year, we reflect on lessons shared by childhood cancer patients and survivors who have faced adversity with grace, courage, and resilience. From their words, come some messages worth remembering now.
Sarah Swaim, age 31, two-time leukemia survivor & advocate

What Is Acute Myeloid Leukemia (AML)?

Dr. Mizukawa is a past St. Baldrick’s Scholar. He explains acute myeloid leukemia symptoms, treatment, and research progress
What is acute myeloid leukemia (AML)?
Leukemia is cancer of the blood cells. Leukemia cells divide quickly and fail to mature into normal, functioning blood cells.
Acute leukemia progresses rapidly and is classified into two general subtypes:
- When the cancer affects the lymphocytes, a type of white blood cell, it is called acute lymphoblastic leukemia, or ALL.
- When the cancer affects other blood cell types, such as red blood cells, platelet-forming cells, and other types of white blood cells, it is called acute myeloid leukemia, or AML.
What Is Acute Lymphoblastic Leukemia (ALL)?

What is acute lymphoblastic leukemia?
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells that normally fight infection. The cells do not grow and develop properly, filling up the bone marrow inside bones, where blood is normally made.
ALL is the most common type of childhood cancer, accounting for 35% of all cancers in children. Each year, there are about 2,900 new cases of children and adolescents diagnosed with ALL in the United States alone.
See how Phineas survived ALL because of research supported by St. Baldrick’s >
Its signs and symptoms resemble other common illnesses, which often leads to other treatments before the leukemia diagnosis is made.
St. Baldrick’s 2018 Holiday Gift Guide: Gifts That Give Kids Hope!
The holiday season is about giving – and what better gift for your loved ones than something that helps a great cause, like taking childhood back from cancer. Not only are the items below awesome gift ideas, but a portion of each sale goes to the St. Baldrick’s Foundation.
That means every item sold helps fund lifesaving research and clinical trials that can find new and better treatments for kids with cancer.
When Research Offers Hope, Parents Continue to Advance the Mission
*Formerly known as the St. Baldrick’s – Stand Up to Cancer Pediatric Cancer Dream Team, this team is now the St. Baldrick’s EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer).
I was recently invited to serve as a patient family advocate for the St. Baldrick’s / Stand Up to Cancer Pediatric Cancer Dream Team representing the National Cancer Institute. If you’re not familiar with the Dream Team and what they’re doing, it’s worth taking a few minutes to read up on the project.
In short, it’s a multi-institutional effort to accelerate cures for childhood cancer by sharing the skill, knowledge and unique resources of 8 top-notch research institutions.

Carlos Sandi with his son, Honored Kid and Ambassador Phineas.
 Older Posts »